Serum Levels of C Type Natriuretic Peptide in Different Reproductive Periods

NCT04000815 | Completed Results

• 1 other identifier: CenkOzay
• Study Type: interventional
• Target: 71
• Locations: 1 country
• Sites: 1

Brief Summary

Recent studies have shown that C natriuretic peptide (CNP) is produced from granulosa cells, increasing cumulative guanosine monophosphate (cGMP) production by affecting cumulus cells through natriuretic peptide receptors.It has been suggested that the transport of cGMP to oocyte via gap junctions causes a continuous increase in cyclic adenosine monophosphate (cAMP) levels within the oocyte. An important role of increased cAMP levels in oocyte is shown to suppress meiotic progression. Deoxyribonucleic acid (DNA) studies in animals have shown that expression of the natriuretic peptide precursor increases during the periovulatory period and shows that this increase decreases rapidly after Luteinizing hormone(LH) / human chorionic(hCG) stimulation. Human studies have shown that after ovulation induction, the CNP level in follicular fluid decreases following ovulatory dose of hCG (9).

Conditions

Serum CNP Levels; Healthy Reproductive Age Women; Healthy Perimenopausal Women; Healthy Postmenopausal Women

Keywords

c type natriuretic peptide; duration of menopause; menstrual cycle

Outcome Measures

Primary Outcomes (1)

• Serum C Type Natriuretic Peptide Levels

  The comparison of serum levels of C type natriuretic peptide among different age groups

  Second or Third Day of Menstruation

Secondary Outcomes (3)

• Correlation Between Serum CNP and Follicle Stimulating Hormone and Luteinizing Hormone Levels in Groups 1 and 2

  Second or Third Day of Menstruation

• Correlation Between Serum CNP and Antral Follicle Count (AFC) in Groups 1 and 2

  Second or Third Day of Menstruation

• Correlation Between Serum CNP and Estradiol Levels in Groups 1 and 2

  Second or Third Day of Menstruation

Study Arms (3)

Reproductive age women

ACTIVE COMPARATOR

The healthy women between 18-40 years old.

Diagnostic Test: C Type Natriüretic Peptide

Perimenopausal women

ACTIVE COMPARATOR

The healthy women between 40-49 years old.

Diagnostic Test: C Type Natriüretic Peptide

Postmenopausal women

ACTIVE COMPARATOR

The healthy women that has been in to menopause more than a year

Diagnostic Test: C Type Natriüretic Peptide

Interventions

C Type Natriüretic Peptide DIAGNOSTIC_TEST

C Type Natriuretic Peptide will be measured with elisa method

Perimenopausal women; Postmenopausal women; Reproductive age women

Eligibility Criteria

• Age: 18 Years - 70 Years
• Gender Eligibility Details: Female participants will be included
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Healthy
• Regular cyclic menstruation for reproductive age group

You may not qualify if:

• No systemic disease(cardiac, renal...etc)
• Smoking
• Drug usage
• Pregnancy

Sponsors & Collaborators

• Near East University, Turkey: lead

Study Sites (1)

Near East University Faculty of Medicine

Nicosia, 99138, Cyprus

Location

Related Publications (9)

• Zhang M, Su YQ, Sugiura K, Xia G, Eppig JJ. Granulosa cell ligand NPPC and its receptor NPR2 maintain meiotic arrest in mouse oocytes. Science. 2010 Oct 15;330(6002):366-9. doi: 10.1126/science.1193573.

  PMID: 20947764 BACKGROUND

• Norris RP, Ratzan WJ, Freudzon M, Mehlmann LM, Krall J, Movsesian MA, Wang H, Ke H, Nikolaev VO, Jaffe LA. Cyclic GMP from the surrounding somatic cells regulates cyclic AMP and meiosis in the mouse oocyte. Development. 2009 Jun;136(11):1869-78. doi: 10.1242/dev.035238.

  PMID: 19429786 BACKGROUND

• Vaccari S, Weeks JL 2nd, Hsieh M, Menniti FS, Conti M. Cyclic GMP signaling is involved in the luteinizing hormone-dependent meiotic maturation of mouse oocytes. Biol Reprod. 2009 Sep;81(3):595-604. doi: 10.1095/biolreprod.109.077768. Epub 2009 May 27.

  PMID: 19474061 BACKGROUND

• Tsafriri A, Chun SY, Zhang R, Hsueh AJ, Conti M. Oocyte maturation involves compartmentalization and opposing changes of cAMP levels in follicular somatic and germ cells: studies using selective phosphodiesterase inhibitors. Dev Biol. 1996 Sep 15;178(2):393-402. doi: 10.1006/dbio.1996.0226.

  PMID: 8812137 BACKGROUND

• Thomas RE, Armstrong DT, Gilchrist RB. Differential effects of specific phosphodiesterase isoenzyme inhibitors on bovine oocyte meiotic maturation. Dev Biol. 2002 Apr 15;244(2):215-25. doi: 10.1006/dbio.2002.0609.

  PMID: 11944932 BACKGROUND

• Nogueira D, Albano C, Adriaenssens T, Cortvrindt R, Bourgain C, Devroey P, Smitz J. Human oocytes reversibly arrested in prophase I by phosphodiesterase type 3 inhibitor in vitro. Biol Reprod. 2003 Sep;69(3):1042-52. doi: 10.1095/biolreprod.103.015982. Epub 2003 May 28.

  PMID: 12773402 BACKGROUND

• Lee KB, Zhang M, Sugiura K, Wigglesworth K, Uliasz T, Jaffe LA, Eppig JJ. Hormonal coordination of natriuretic peptide type C and natriuretic peptide receptor 3 expression in mouse granulosa cells. Biol Reprod. 2013 Feb 21;88(2):42. doi: 10.1095/biolreprod.112.104810. Print 2013 Feb.

  PMID: 23255339 BACKGROUND

• Hiradate Y, Hoshino Y, Tanemura K, Sato E. C-type natriuretic peptide inhibits porcine oocyte meiotic resumption. Zygote. 2014 Aug;22(3):372-7. doi: 10.1017/S0967199412000615. Epub 2013 Jan 18.

  PMID: 23331536 BACKGROUND

• Kawamura K, Cheng Y, Kawamura N, Takae S, Okada A, Kawagoe Y, Mulders S, Terada Y, Hsueh AJ. Pre-ovulatory LH/hCG surge decreases C-type natriuretic peptide secretion by ovarian granulosa cells to promote meiotic resumption of pre-ovulatory oocytes. Hum Reprod. 2011 Nov;26(11):3094-101. doi: 10.1093/humrep/der282. Epub 2011 Aug 23.

  PMID: 21865234 BACKGROUND

Limitations and Caveats

The most prominent limitation of our study was the relatively small number of participants. This avoided us from using more powerful parametric tests for statistical analysis.

Results Point of Contact

• Title: Dr.Ali Cenk Ozay
• Organization: Dr.Ali Cenk Ozay

dr.alicenk@hotmail.com

00905428583248

Study Officials

• Özay

  Near East University

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: SINGLE
• Who Masked: INVESTIGATOR
• Purpose: DIAGNOSTIC
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Medical Doctor

Model Details: In this study, there are three groups. Group 1:Women between 18-40 age, Group 2:Perimenopausal women (40-49 years), Group 3: Postmenopausal women.

Study Record Dates

• First Submitted: June 22, 2019
• First Posted: June 27, 2019
• Study Start: July 24, 2019
• Primary Completion: January 9, 2020
• Study Completion: January 20, 2020
• Last Updated: March 11, 2020
• Results First Posted: March 11, 2020

Record last verified: 2020-03

Data Sharing

• IPD Sharing: Will not share

Locations

CY (1)